Immune-Onc, University of Texas discover new AML target
A study published Wednesday in Nature revealed a checkpoint inhibitor target for acute myelogenous leukemia, adding a new mechanism of action for an indication that, until recently, has been a new drug wasteland. Immune-Onc Therapeutics Inc. (Palo Alto, Calif.), which co-authored the Nature paper, plans to develop an antibody against the target for AML.
That antibody, dubbed IO-202, targets leukocyte immunoglobin-like receptor, subfamily B, member 4 (LILRB4; CD85k; ILT3). Immune-Onc expects to submit an IND next year for IO-202, its lead program. The company has exclusive, worldwide rights to the antibody from its partners and study co-authors University of Texas Health Science Center and the University of Texas Southwestern Medical Center...